Pomerantz LLP is investigating Sellas Life Sciences Group and some of its officers for possible securities fraud after the company delayed releasing results from a key phase 3 clinical trial for its drug Galinpepimut-S. The trial reached a critical event with the 80th patient death on August 28, 2026, which should have triggered result disclosure, but Sellas did not release the data as expected. Following this news, Sellas's stock price dropped 13.15% to $13.21. The investigation aims to determine if the company engaged in unlawful business practices, with potential class action participation available for investors.
The investigation into Sellas Life Sciences Group provides context for health sector activity on Pluang. Of 100 priced health-sector US stocks, 30 rose and 67 fell today. Notable movers include NUWE at USD 0.76 with a 5.53% gain, MCK at USD 897.98 up 5.17%, and CLPT at USD 11.64 down 4.67%, as of Oct 01, 2026 20:52 WIB.
Vannor introduced an agentic marketing model featuring autonomous AI agents that independently manage marketing tasks from research to content publication and optimization. Running on Vannor-owned NVIDIA AI hardware, these agents increased the compan...
The DIVB ETF is rated a Buy due to its superior risk-adjusted returns and balanced approach combining dividends and share buybacks, avoiding heavy concentration in mega-cap stocks. Since inception, DIVB has delivered a 14.35% annualized return, outpe...
Solana's network growth has surged 124% since early September, with 1.71 million new wallets created daily and daily active addresses up 58%. This increase in users and activity strengthens Solana's ecosystem and could support higher market value ove...
Pitney Bowes has received a buy rating due to improving profitability and robust cash flows, even as its revenues decline. The SendTech Solutions segment notably drives profit growth, with adjusted EBITDA rising 17% and EBIT increasing 21% year-over-...
Cardano experienced a surge with 413 transfers exceeding $100,000 in a single day, marking its highest activity since June 4. The Cardano Foundation's application for the .ada generic top-level domain has progressed to the next phase in ICANN's 2026 ...
